Search
PF-00610355
go.drugbank.com/drugs/DB11871InvestigationalPF-00610355 has been used in trials studying the treatment of Lung Disease, Moxifloxacin, Pulmonary Disease, Asthma, Bronchial, and Bronchial Diseases, among others.
Ferrous bisglycinate
go.drugbank.com/drugs/DB11210ApprovedFerrous bisglycinate is a chelate that is used as a source of dietary iron. Forming a ring structure when reacting with glycine, ferrous bisglycinate acts as both a chelate and a nutritionally functional . It is found in foods for food e...
Mixtures: PR Natal 430, PR Natal 400Ampicillin
go.drugbank.com/drugs/DB00415ApprovedInvestigationalVet approvedAmpicillin is a semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.
Mixtures: Ampicillin/Sulbactam Astro 3 g Pulver zur Herstellung einer Injektions- oder Infusionslösung, Ampicillin/Sulbactam Astro 1,5 g Pulver zur Herstellung einer Injektions- oder InfusionslösungPF-03882845
go.drugbank.com/drugs/DB11814InvestigationalPF-03882845 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 and Type 2 Diabetic Nephropathy.
Tomivosertib
go.drugbank.com/drugs/DB15219InvestigationalTomivosertib is under investigation in clinical trial NCT03318562 (A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC).
Benmelstobart
go.drugbank.com/drugs/DB17473InvestigationalAPL 502 is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1 (PD-L1).
TP-271
go.drugbank.com/drugs/DB15040InvestigationalTP-271 is under investigation in clinical trial NCT02724085 (A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271).
PT-2385
go.drugbank.com/drugs/DB16055InvestigationalPT-2385 is under investigation in clinical trial NCT03108066 (PT2385 for the Treatment of Von Hippel-lindau Disease-associated Clear Cell Renal Cell Carcinoma).
Adenine
go.drugbank.com/drugs/DB00173ApprovedInvestigationalNutraceuticalA purine base and a fundamental unit of adenine nucleotides.
Mixtures: CPD/ADSOL Red Cell Preservation Solution System (PL 2209), CPD/ADSOL Red Cell Preservation Solution System (PL 2209)Larotrectinib
go.drugbank.com/drugs/DB14723ApprovedInvestigationalIt was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.[L4847]. On April 10, 2025, the FDA granted full drug approval.[L52805]
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates